RT Journal Article
SR Electronic
T1 Major new lineages of SARS-CoV-2 emerge and spread in South Africa during lockdown
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.28.20221143
DO 10.1101/2020.10.28.20221143
A1 Tegally, Houriiyah
A1 Wilkinson, Eduan
A1 Lessells, Richard R
A1 Giandhari, Jennifer
A1 Pillay, Sureshnee
A1 Msomi, Nokukhanya
A1 Mlisana, Koleka
A1 Bhiman, Jinal
A1 Allam, Mushal
A1 Ismail, Arshad
A1 Engelbrecht, Susan
A1 Van Zyl, Gert
A1 Preiser, Wolfgang
A1 Williamson, Carolyn
A1 Pettruccione, Francesco
A1 Sigal, Alex
A1 Gazy, Inbal
A1 Hardie, Diana
A1 Hsiao, Marvin
A1 Martin, Darren
A1 York, Denis
A1 Goedhals, Dominique
A1 San, Emmanuel James
A1 Giovanetti, Marta
A1 Lourenco, Jose
A1 Alcantara, Luiz Carlos Junior
A1 de Oliveira, Tulio
YR 2020
UL http://medrxiv.org/content/early/2020/10/30/2020.10.28.20221143.abstract
AB In March 2020, the first cases of COVID-19 were reported in South Africa. The epidemic spread very fast despite an early and extreme lockdown and infected over 600,000 people, by far the highest number of infections in an African country. To rapidly understand the spread of SARS-CoV-2 in South Africa, we formed the Network for Genomics Surveillance in South Africa (NGS-SA). Here, we analyze 1,365 high quality whole genomes and identify 16 new lineages of SARS-CoV-2. Most of these unique lineages have mutations that are found hardly anywhere else in the world. We also show that three lineages spread widely in South Africa and contributed to ∼42% of all of the infections in the country. This included the first identified C lineage of SARS-CoV-2, C.1, which has 16 mutations as compared with the original Wuhan sequence. C.1 was the most geographically widespread lineage in South Africa, causing infections in multiple provinces and in all of the eleven districts in KwaZulu-Natal (KZN), the most sampled province. Interestingly, the first South-African specific lineage, B.1.106, which was identified in April 2020, became extinct after nosocomial outbreaks were controlled. Our findings show that genomic surveillance can be implemented on a large scale in Africa to identify and control the spread of SARS-CoV-2.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was funded by The South African Medical Research Council (SAMRC), MRC SHIP and the Department of Science and Innovation (DSI) of South Africa. KRISP is funded by a core award of the South African Technology Innovation Agency (TIA).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The project was approved by University of KwaZulu-Natal Biomedical Research Ethics Committee. Protocol reference number: BREC/00001195/2020. Project title: COVID-19 transmission and natural history in KwaZulu-Natal, South Africa: Epidemiological Investigation to Guide Prevention and Clinical Care. This project was also approved by University of the Witwatersrand Human Research Ethics Committee. Clearance certificate number: M180832. Project title: Surveillance for outpatient influenza-like illness and asymptomatic virus colonization in South Africa. Sequence data from the Western Cape was approved by the Stellenbosch University HREC Reference No: N20/04/008_COVID-19. Project Title: COVID-19: sequencing the virus from South African patients.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll of the sequence data, i.e. 1365 whole genomes of SARS-CoV-2, have been deposited at GISAID.